JOHNSON & JOHNSON
JOHNSON & JOHNSON (JNJ): 300 pipeline candidates · 3 upcoming catalysts · ~10 mo cash runway · 43 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
10.4 months
D/E 1.47
N/A
300 candidates
3 upcoming, next in ~743d
0 buys · 17 sells (180d)
A transparent, data-derived signal for JOHNSON & JOHNSONacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$560.3B
Cash
$21.7B
Quarterly Burn
$9.6B
Runway
10.4 mo
Revenue
$24.1B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (300 candidates)
Showing 10 of 300 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4,593
Total value held
$451.94B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 313,210,740 | $76.56B |
| blackrock, inc. | 213,385,546 | $52.16B |
| state street corp | 133,476,288 | $32.63B |
| vanguard portfolio management llc | 63,514,436 | $15.53B |
| geode capital management, llc | 59,164,862 | $14.42B |
| morgan stanley | 44,721,167 | $10.93B |
| state farm mutual automobile insurance co | 31,590,952 | $7.72B |
| northern trust corp | 29,319,669 | $7.17B |
| bank of america corp /de/ | 25,516,697 | $6.24B |
| fmr llc | 24,771,828 | $6.06B |
Showing top 10 of 4,593 institutional holders of JOHNSON & JOHNSON. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in JOHNSON & JOHNSON's pipeline?
JOHNSON & JOHNSON (JNJ) has 300 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is JOHNSON & JOHNSON's next catalyst?
JOHNSON & JOHNSON's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy i" — expected June 30, 2028.
What is JOHNSON & JOHNSON's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, JOHNSON & JOHNSON has approximately 10.4 months of cash runway.
What is JOHNSON & JOHNSON's market capitalization?
JOHNSON & JOHNSON's market capitalization is approximately $560.3B.
Who is the CEO of JOHNSON & JOHNSON?
Mr. Joaquin Duato is the chief executive officer of JOHNSON & JOHNSON (JNJ).
Get the full picture on JOHNSON & JOHNSON
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.